Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24 week, double blind, randomized study to investigate the effect of 500 microg Roflumilast tablets once daily versus placebo on parameters indicative of hyperinflation in patients with chronic obstructive pulmonary disease.

Trial Profile

A 24 week, double blind, randomized study to investigate the effect of 500 microg Roflumilast tablets once daily versus placebo on parameters indicative of hyperinflation in patients with chronic obstructive pulmonary disease.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Roflumilast (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms HERO

Most Recent Events

  • 04 May 2012 Additional lead trial investigator (D. Bredenbroker) identified as reported by ClinicalTrials.gov.
  • 04 May 2012 Company added to the associations field as reported by ClinicalTrials.gov record.
  • 25 Jan 2012 Additional trial identifier (NCT00108823) identified as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top